TWIN-PEIC: Physical Exam Indicated Cerclage in Twin Gestations

Sponsor
Thomas Jefferson University (Other)
Overall Status
Terminated
CT.gov ID
NCT02490384
Collaborator
Columbia University (Other), Federico II University (Other), Albany Medical College (Other), University of Rochester (Other), George Washington University (Other), Wright State University (Other), Baystate Medical Center (Other), Università degli Studi di Brescia (Other), University of Bologna (Other), University Hospital, Geneva (Other), University of Warsaw (Other), Maternal Fetal Medicine Associates (Other)
30
11
2
54.4
2.7
0.1

Study Details

Study Description

Brief Summary

This is a multicenter randomized study designed to determine if physical exam indicated cerclage reduces the incidence of spontaneous preterm birth <34 weeks in asymptomatic women with twin gestations and dilated cervix, diagnosed by pelvic exam between 16 to 23 6/7 weeks of gestation.

Condition or Disease Intervention/Treatment Phase
  • Procedure: Physical exam indicated cerclage
N/A

Detailed Description

Twin pregnancies have 58% incidence of preterm delivery (before 37 weeks of gestation), with increased perinatal mortality and neonatal morbidity. No therapy has proven effective in preventing preterm birth in twins. When cervical dilation is identified before 24 weeks in singleton pregnancies, the risk of preterm birth is 90%-100%; based on a small series of cases, approximately 50% of twin gestations with cervical dilation will be delivered prior to viability (24 weeks) and the risk of preterm birth prior to 34 and 37 weeks was 85% and 100%. Cervical dilation is the worst prognostic factor for preterm birth. There are a small number of case reports of cervical cerclage in twin pregnancies with a dilated cervix that suggest similar outcomes to those in singleton pregnancies. The investigators' objective is to determine if physical exam indicated cerclage reduces the incidence of spontaneous preterm birth <34 weeks and improve perinatal outcome in asymptomatic women with twin gestations and dilated cervix (1 to 5 cm) between 16 to 23 6/7 weeks of gestation.

Study Design

Study Type:
Interventional
Actual Enrollment :
30 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
None (Open Label)
Primary Purpose:
Treatment
Official Title:
Randomized Control Trial Physical Exam Indicated Cerclage in Twin Gestations
Actual Study Start Date :
Jun 1, 2015
Actual Primary Completion Date :
Dec 1, 2019
Actual Study Completion Date :
Dec 12, 2019

Arms and Interventions

Arm Intervention/Treatment
Active Comparator: Physical exam indicated cerclage

Cerclage

Procedure: Physical exam indicated cerclage
Cervical cerclage

No Intervention: Expectant management

No cerclage

Outcome Measures

Primary Outcome Measures

  1. Preterm delivery less than 34 weeks [at delivery]

    Incidence of preterm birth less than 34 weeks (any indication)

Secondary Outcome Measures

  1. Spontaneous preterm birth less than 34 [at delivery]

    Incidence of spontaneous preterm birth less than 34 weeks

  2. Preterm delivery less than <32 weeks, <28 weeks, or <24 weeks [at delivery]

    Incidence of preterm birth less than <32 weeks, <28 weeks, or <24 weeks

  3. Mean gestational age at delivery [at delivery]

    Mean value of gestational age at delivery (weeks)

  4. Birth weight at birth [at delivery]

    Mean value (grams)

  5. Gestational age at spontaneous rupture of membranes [at presentation of rupture membranes]

    Mean value (weeks) through study completion

Other Outcome Measures

  1. Chorioamnionitis [Time of delivery]

    Incidence

  2. Composite adverse neonatal outcome [Incidence between birth and 28 days of age]

    Includes necrotizing enterocolitis, intraventricular hemorrhage (grade 3 or higher), respiratory distress syndrome, bronchopulmonary dysplasia, retinopathy, blood-culture proven sepsis

  3. Fetal demise [Incidence before delivery]

    Incidence

  4. Neonatal death [Incidence between birth and 28 days of age]

    Incidence

  5. Perinatal death [Incidence before and after birth ulntil 28 days of age]

    Incidence

  6. Maternal death [Between birth and 6 weeks postpartum]

    Incidence

  7. Interval between diagnosis and delivery [at delivery]

    Mean value (days) through study completion

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years to 60 Years
Sexes Eligible for Study:
Female
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  1. Pregnant women older than 18 years of age

  2. Diamniotic twin pregnancy

  3. Cervical dilation between 1 to 5 cm and/or visible membranes by pelvic exam or speculum exam between at 16-23 6/7 weeks gestation

Exclusion Criteria:
  1. Singleton pregnancy or higher order than twins multiple gestation

  2. Cervical dilation more than 5 cm

  3. Amniotic membranes prolapsed beyond external os into the vagina, unable to visualize cervical tissue

  4. More than 24 weeks of gestation

  5. Multifetal reduction after 14 weeks

  6. Monoamniotic twins

  7. Twin-twin transfusion syndrome

  8. Ruptured amniotic membranes at the time of diagnosis of dilated cervix

  9. Major fetal structural anomaly

  10. Fetal chromosomal abnormality

  11. Cerclage already in place for other indications

  12. Active vaginal bleeding

  13. Suspicion of clinical or biochemical chorioamnionitis

  14. Painful regular uterine contractions

  15. Labor (progressing cervical dilation)

  16. Placenta previa

Contacts and Locations

Locations

Site City State Country Postal Code
1 George Washington University Washington District of Columbia United States 20037
2 Albany Medical Center Albany New York United States 12208
3 Columbia University Medical Center New York New York United States 10032
4 University of Rochester Medical Center Rochester New York United States 14642
5 Wright State University Dayton Ohio United States 45409
6 Thomas Jefferson University Hospital Philadelphia Pennsylvania United States 19107
7 Austin Maternal Fetal Medicine St David's Health Care Austin Texas United States 78758
8 Bologna University Bologna Italy
9 University of Brescia Brescia Italy
10 Università degli Studi di Napoli "Federico II" Naples Italy
11 University of Warsaw Warsaw Poland

Sponsors and Collaborators

  • Thomas Jefferson University
  • Columbia University
  • Federico II University
  • Albany Medical College
  • University of Rochester
  • George Washington University
  • Wright State University
  • Baystate Medical Center
  • Università degli Studi di Brescia
  • University of Bologna
  • University Hospital, Geneva
  • University of Warsaw
  • Maternal Fetal Medicine Associates

Investigators

  • Principal Investigator: Amanda Roman, MD, amanda.roman@jefferson.edu

Study Documents (Full-Text)

More Information

Publications

Responsible Party:
Thomas Jefferson University
ClinicalTrials.gov Identifier:
NCT02490384
Other Study ID Numbers:
  • ThomasJeffersonU
First Posted:
Jul 3, 2015
Last Update Posted:
Apr 27, 2020
Last Verified:
Apr 1, 2020
Individual Participant Data (IPD) Sharing Statement:
Yes
Plan to Share IPD:
Yes
Keywords provided by Thomas Jefferson University
Additional relevant MeSH terms:

Study Results

No Results Posted as of Apr 27, 2020